— Know what they know.
Not Investment Advice
Also trades as: 0K6R.L (LSE) · $vol 0M

NBIX Short Interest

Neurocrine Biosciences, Inc.
1W: +2.9% 1M: +4.0% 3M: -19.2% YTD: +3.9% 1Y: +1.4% 3Y: +32.3% 5Y: +41.6%
$146.00
+0.13 (+0.09%)
 
Weekly Expected Move ±3.9%
$131 $137 $143 $148 $154
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 60 · $14.8B mcap · 100M float · 1.28% daily turnover · Short 73% of daily vol
Credit Risk of going bust: lower than 88% of companies Debt: 2.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.30 (down 99.8%), Neurocrine Biosciences, Inc. would be worth roughly what it owes.
Total debt $401.8M against a stock market value of $14.84B.
Distance to default 12.82 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $200.9M (short-term plus half of long-term), stock volatility 34.0%; Altman Z'' 4.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Short Volume Summary

2026-10-26
71.8%
Short Ratio
of total volume
66.2%
20-Day Avg
62.1%
50-Day Avg
▲ Rising
5-Day Trend
0.3M
Short Volume
0.5M
Total Volume

Daily Short Volume Ratio

Short Volume vs Total Volume

Exchange Breakdown

2026-10-26
ExchangeShort VolumeTotal VolumeShort %
NASDAQ 320,511 452,659 70.8%
NYSE 29,174 34,056 85.7%
BATS 93 177 52.6%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms